Related references
Note: Only part of the references are listed.2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
Cristina Ponte et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Bernhard Hellmich et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Risk factors for severe cranial ischaemic complications in giant cell arteritis
Alojzija Hocevar et al.
RHEUMATOLOGY (2020)
Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study
Anael Dumont et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Delays in the management of ocular complications of giant cell arteritis: A retrospective monocentric study of 33 patients
T. Sene et al.
REVUE DE MEDECINE INTERNE (2020)
Trial of Tocilizumab in Giant-Cell Arteritis
J. H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients
Eric Liozon et al.
JOURNAL OF RHEUMATOLOGY (2016)
mice: Multivariate Imputation by Chained Equations inR
Stef van Buuren et al.
Journal of Statistical Software (2015)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette et al.
ARTHRITIS AND RHEUMATISM (2013)
Guidelines for Care of the Hospitalized Patient with Hyperglycemia and Diabetes
Kate Crawford
CRITICAL CARE NURSING CLINICS OF NORTH AMERICA (2013)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Gene G. Hunder et al.
ARTHRITIS AND RHEUMATISM (2010)
Drug-Induced Hyperglycemia: a Study in the French Pharmacovigilance Database.
Leila Chebane et al.
THERAPIE (2010)
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition
C. T. Berger et al.
RHEUMATOLOGY (2009)
Systemic tolerance of corticosteroid therapy in ophthalmology depending on the route of administration
S. Feldman-Billard et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2008)
Risk factors for early visual deterioration in temporal arteritis
Tobias Loddenkemper et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Poor prognosis of visual outcome after visual loss from giant cell arteritis
H Danesh-Meyer et al.
OPHTHALMOLOGY (2005)
Short-term tolerance of three days pulse methyprednisolone therapy: a prospective study in 146 patients
S Chibane et al.
REVUE DE MEDECINE INTERNE (2005)
Risk factors for cranial ischemic complications in giant cell arteritis
G Nesher et al.
MEDICINE (2004)
Propensity score estimation with boosted regression for evaluating causal effects in observational studies
DF McCaffrey et al.
PSYCHOLOGICAL METHODS (2004)
Intravenous pulse methylprednisolone therapy in eye disease -: Effect on glucose tolerance
S Feldman-Billard et al.
OPHTHALMOLOGY (2003)
Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy
SS Hayreh et al.
OPHTHALMOLOGY (2003)
Recovery of visual function in patients with biopsy-proven giant cell arteritis
R Foroozan et al.
OPHTHALMOLOGY (2003)
Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature
SS Hayreh et al.
ACTA OPHTHALMOLOGICA SCANDINAVICA (2002)
Steroid management in giant cell arteritis
CCK Chan et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2001)
Visual manifestations of giant cell arteritis -: Trends and clinical spectrum in 161 patients
MA González-Gay et al.
MEDICINE (2000)
Optic disk and retinal nerve fiber layer damage after transient central retinal artery occlusion: An experimental study in rhesus monkeys
SS Hayreh et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2000)
Share Paper
